Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 19 20 21 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Adheron Therapeutics–Abzena: antibody technology, 201510 existent lead product SDP051 uses Abzena’s Composite Human Antibody technology 2015-10-09
Adheron Therapeutics–Roche: investment, 201510 acquisition $105m upfront cash + $475m milestones 2015-10-09
Affimed–OTHER: investment, 201510 investment €19.2m purchase of 3.3m shares by existing shareholder 2015-10-09
NEO New Oncology–Akampion: public relations, 201510 service existent by Akampion 2015-10-09
NEO New Oncology–SEVERAL: investment, 201510 financing round €5m 2015-10-09
Glycotope–Octapharma: investment, 201510 acquisition of new shares by Octapharma as part of excl license deal 2015-10-08
Octapharma–Glycotope: protein expression technology, 201510– license ww excl to human coagulation factors based on GEX technology 2015-10-08
Merck (US)–Proteros: drug discovery services, 201510– collab €na upfront + research funding + $126m milestones + royalties r+d small mol cancer drug 2015-10-07
Nestlé–Lipotype: lipidomics research, 201510 collab existent use of Lipotype technology for lipid analysis in nutritional research NIHS 2015-10-07
Probiodrug–Rentschler: biological contract manufacturing, 201510– process developm + production of PBD-C06 for pre-clinical + clinical studies 2015-10-07
Marinomed–Austria (govt): investment, 201510 aws Mittelstandsfonds aquires share in Marinomed 2015-10-06
EMBL–IBM: software tools, 201510– supply EMBL deploys Aspera s/w for fast + reliable data transfer 2015-10-05
Fianostics–Sony: fluorescence immunoassay platform, 201510– collab contract manufacturing for MEF assay platform by Sony DADC BioSciences 2015-10-05
Affimed–Aeris Capital: investment, 201510 investment $21.8m for 3.3m shares by existing investor Aeris Capital 2015-10-01
Opti-Lab–Omnilab (DE): investment, 201510 acqu of additonal shares resulting in majority for Omnilab w sole minority owner now Sebastian Haselhun 2015-10-01
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech 2015-10-01
Tizona Therapeutics–Minapharm: GlymaxX technology, 201510– license + contract manufacturing agreem for use of GlymaxX for cancer antibody ProBioGen AG 2015-10-01
United States (govt)–Evotec: compound management, 201510–202009 supply service up to €4.5m to NCI Chemical Biology Consortium 2015-10-01
Sanofi–Pieris: anticalin technology, 2015Q3 collab existent developm of anti-infectives 2015-09-30
Asceneuron–SEVERAL: investment, 201509 financing round Series A CHF30m led by Sofinnova Partners 2015-09-29
Infinity Pharmaceuticals–Max Planck: drug discovery services, 201509– collab in cancer using LDC network with MPG + Helmholtz 2015-09-29
Zinc Ahead–Veeva Systems: investment, 201509 acquisition $130m in cash incl $10m deffered consideration over 3 years 2015-09-29
JnJ–Protectimmun: asthma drug, 201509 collab research JnJ Innovation funding preclinical study at Imperial College Protectimmune lead candidate 2015-09-28
Beijing Clear Biotech–Curetis: Unyvero platform, 201509– distribution excl in Greater China of system + 2 cartridges by BCB 2015-09-25
Nabriva–SEVERAL: investment, 201509 US IPO $92.25m with 9m ADSs at $10.25/ADS at Nasdaq 2015-09-23
Nestlé–AC Immune: Alzheimer test, 201509– collab r+d minimally invasive Tau Dx assay Néstle Institute of Health Sciences 2015-09-23
Zedira–Cardiff Univ: drug discovery, 201509– collab research role of transglutaminase 6 in disease pathway of cerebellar ataxia 2015-09-22
Qiagen–PathoFinder: molecular diagnostics, –201509 collab developm + production of RespiFast RG Panel for Rotor-Gene Q MDx instrument 2015-09-21
Biametrics–SEVERAL: investment, 201509 financing round Series A €3.1m from LBBW Venture + MBG BW + KfW 2015-09-18
French Myopathy Association–Cevec: cell line technology, 201509– license €na to use CAP GT technology for lentivirus cell line developm to Généthon 2015-09-17
Sigma-Aldrich–IROA Technologies: compound library, 201509– distribution ww excl of Mass Spectrometry Metabolite Library of Standards (MSMLS) by Sigma 2015-09-17
Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform 2015-09-17
Evolva–SEVERAL: investment, 201509 rights offering CHF57.4m 2015-09-16
Nestlé–Lipid Therapeutics: gastrointestinal drug, 201609– license excl to develop + market LT-02 ww excl Europe + Australia to Nestlé Health Science 2015-09-16
Forbion–SEVERAL: investment, 201509 closing €75m of FCF II Co-invest Fund I incl Coller Capital + Hamilton Lane + KLP 2015-09-10
IAVI–CureVac: mRNA technology, 201509– collab using RNActive technology to deliver HIV immunogens for developm of AIDS vaccines 2015-09-10
Lophius–SEVERAL: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF 2015-09-10
Venneos–High-Tech Gründerfonds: investment, 201509 seed financing round totalling €1m from HTGF + Max Planck + business angels + family offices 2015-09-10
Venneos–Max Planck: investment, 201509 seed financing round totalling €1m from HTGF + Max Planck + business angels + family offices 2015-09-10
Venneos–SEVERAL: investment, 201509 seed financing round €1m from HTGF + Max Planck + business angels + family offices 2015-09-10
Lophius–High-Tech Gründerfonds: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF 2015-09-09
Phenomenex–Tecan: automated liquid handling, 201509– collab co-marketing Strata + Strata-X SPE sorbents with Freedom EVO platform 2015-09-08
Pierre Fabre–Addex: CNS drugs, 201509– license option for mGlu3 receptor program to Pierre Fabre Pharmaceuticals 2015-09-08
Lumora–Erba Diagnostics Mannheim: investment, 201509 acquisition of Lumora Ltd renamed Erba Molecular Ltd 2015-09-07
ADC Therapeutics–Instinctif Partners: public relations, 201509 service existent by Instinctif Partners for ADCT 2015-09-02
ADC Therapeutics–SEVERAL: investment, 201509 financing round $80m of ADC Therapeutics incl Auven + AstraZeneca et al 2015-09-02
Baxalta–Novimmune: therapeutic antibodies, 201509– collab r+d €na bispecific antibodies for hemophilia A 2015-09-02
Boehringer–Vectron Biosolutions: gene expression technology, 201509– license non-excl to Vectron technology for use w BI e. coli production system 2015-09-01
Chemie Brunschwig–Link Technologies: reagents, 201509– distribution in Switzerland by Chemie Brunschwig AG 2015-09-01
Intellia Therapeutics–Novartis: investment, 201509 financing round Series B totalling $70m led by OrbiMed + incl co-investor Novartis 2015-09-01
Intellia Therapeutics–SEVERAL: investment, 201509 financing round Series B $70m led by OrbiMed HealthCare Fund Management 2015-09-01
Labfolder–SEVERAL: investment, 201509 financing round € 7-digit led by Charité Biomedical Fund (CBF-1) 2015-09-01
Pfizer–Evotec: drug discovery services, 201509– collab + license agreem 4 years to develop anti-fibrotics 2015-09-01
Hisun Pharmaceutical–IMD Natural Solutions: drug discovery, 201508– collab using IMD natural product lead discovery platform incl €4m investment 2015-08-31
IMD Natural Solutions–Hisun Pharmaceutical: investment, 201508 equity investment €4m as part of collab with Zhejiang Hisun Pharmaceutical Co Ltd 2015-08-31
GSK–LimmaTech Biologics: vaccines, 201508– collab at least 5y using former GlycoVaxyn technology to develop vaccines owned by GSK 2015-08-28
Immatics–Texas (govt): grant, 201508 launch of Immatics US Inc supported by $19.7m grant from CPRIT 2015-08-26
Immatics–Univ Texas: cell therapy, 201508– collab launch joint venture Immatics US Inc with MD Anderson to advance adoptive cellular therapies 2015-08-26
Merus–Novartis: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round incl existing investor Novartis Venture Fund 2015-08-26
Merus–SEVERAL: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round 2015-08-26
GeneWorks–Genetrix (ES): genomic reagents, 201508– distribution non-excl Sygnis TruePrime + SunScript RT products in Australia 2015-08-25
MorphoSys–Immatics: cancer immunotherapy, 201508– collab strategic alliance r+d using Xpresident + Ylanthio platforms 2015-08-25
Osthus–Dotmatics: bioinformatics, 201508– collab combined services + product offering for RnD IT for life sciences 2015-08-24
Roche–Lumora: nucleic acid purification, 201508 acquisition €na of Heat Elution purifition technoloyg assets by Roche 2015-08-24
Freudenberg–CMS: legal services, 201508 legal advice by CMS Hasche Sigle on acquisition of Hemoteq AG by Freudenberg Medical Europe GmbH 2015-08-21
Hemoteq–Freudenberg: investment, 201508 acquisition of 74.9% majority share in Hemoteq AG by Freudenberg Medical Europe GmbH 2015-08-21
Novartis–GSK: ofatumumab, 201508 acquisition of all rights to all indications for Arzerra for up to $1.034b by Novartis 2015-08-21
Nanodigmbio–Genetrix (ES): genomic reagents, 201508– distribution of Sygnis TruePrime + SunScript RT products in China by Nanodigmbio 2015-08-20
EBS Technologies–Earlybird: investment, 201508 financing round totalling €1.1m led by returning investors Earlybird + HTGF 2015-08-19
EBS Technologies–High-Tech Gründerfonds: investment, 201508 financing round totalling €1.1m led by returning investors Earlybird + HTGF 2015-08-19
EBS Technologies–PERSON: investment, 201508 financing round €1.1m led by Earlybird + HTGF plus 3 private investors incl R Christine 2015-08-19
EBS Technologies–SEVERAL: investment, 201508 financing round €1.1m led by Earlybird + HTGF plus 3 private investors incl R Christine 2015-08-19
Kapa Biosystems–Roche: investment, 201508 acquisition €na by Roche ANNOUNCED 2015-08-19
Celsus Therapeutics–SEVERAL: investment, 201508– private placement $75m net $70m of ADSs led by Deerfield 2015-08-18
Kuros–Huntsworth: public relations, 201508 service existent media relations by Citigate Dewe Rogerson 2015-08-18
Kuros–SEVERAL: investment, 201508 financing round CHF15m led by LifeCare Partners + Life Sciences Partners 2015-08-18
GeneWeave–Roche: investment, 201508– acquisition $190m upfront + $235m product related milestones 2015-08-13
Checkmate–Cytos Biotechnology: cancer immunotherapy, 201508– excl license to CYT003 + VLP technology for cancer $90m milestones + royalties 2015-08-12
Checkmate–SEVERAL: investment, 201508 financing round Series A $20m from Sofinnova Ventures + venBio 2015-08-12
Sanofi–Apeiron: cancer immunotherapy, 201508– collab r+d small-molecules of Evotec + Apeiron + Sanofi 2015-08-10
Sanofi–Evotec: cancer immunotherapy, 201508– collab r+d small-molecules of Evotec + Apeiron + Sanofi 2015-08-10
JenaValve–SEVERAL: investment, 201508 financing round $26.5m including Gimv 2015-08-07
Nomad Bioscience–Denka: investment, 201508–201708 acquisition up to €75m of 51% share in Icon Genetics GmbH + after 2y acquiring rest by Denka 2015-08-07
Sanofi–Evotec: drug discovery, 201508– collab research beta cell replacement therapy for diabetes 2015-08-07
Deutsche Biotech Innovativ–Kirchhoff Consult: public relations, 201508 service existent by Kirchhoff Consult AG 2015-08-06
MorphoSys–G7 Therapeutics: therapeutic antibodies, 201508– collab to develop therap ABs targeting GPCRs 2015-08-04
AdvanceCor–SEVERAL: investment, 201508 2nd financing round €2.2m led by MIG AG inkl Bayern Kapital + Bio-M + HTGF + KfW Bank + founders 2015-08-01
Amgen–Novartis: CNS drugs, 201508– collab ww developm + commercialisation drugs for Alzheimer’s + migraine 2015-08-01
Deutsche Biotech Innovativ–SEVERAL: investment, 201508–201511 capital increase €1.6m 49k new shares €33.5/share out of 596.4k shares on public offer 2015-08-01
Novartis–CSL: investment, 201507 acquisition $275m of Novartis influenza vaccine business by CSL Ltd 2015-07-31
Santhera–SEVERAL: investment, 201507–201508 capital increase $28.6m 2015-07-31
DSM–Evonik: animal feed, 201507– collab developm algae-based production of omega-3 fatty acids for animal nutrition 2015-07-29
Mereo BioPharma–Novartis: investment, 201507 Novartis receives equity stake in consideration for acquisition of 3 programmes from Novartis by Mereo 2015-07-29
Mereo BioPharma–SEVERAL: investment, 201507 financing round $118m from Woodford + Invesco Perpetual at launch of company 2015-07-29
Apogenix–R-Biopharm: cancer companion diagnostics, 201507– collab developm CDx for Apogenix’ CD95 ligand inhibitor APG101 2015-07-28
Boehringer–Hanmi: kinase inhibitor, 201507–201609 TERMINATED license to HM61713 ww excl KR + CN + HK with $50m upfront + $680m milestones + royalties 2015-07-28
Boehringer–Hikma: investment, 201507– acquisition of Roxane Labs $2.65b w $1.18m in cash + 40m new Hikma shares + addit $125m milestones 2015-07-28
Hikma–Boehringer: investment, 201507– acquisition 40m new shares £940m representing 16.71% as part of sale of Roxane by BI to Hikma 2015-07-28
MRC Technology–Univ Göttingen: therapeutic antibodies, 201507– collab developm ABs targeting amyloid beta 4-x for Alzheimer’s Disease 2015-07-28
Pieris–SEVERAL: investment, 201507 public offering $25m+$3.3m with 9.1m+1.2m new shares common stock $2.75/share 2015-07-28
next pagenext page 1 2 3 ... 19 20 21 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top